News stories about Johnson & Johnson (NASDAQ:JNJ
) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Johnson & Johnson earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.1596430415946 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Johnson & Johnson (JNJ
) traded down 0.92% on Friday, reaching $130.98. The company’s stock had a trading volume of 4,854,414 shares. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The company’s 50 day moving average price is $132.48 and its 200-day moving average price is $128.74. The stock has a market cap of $351.55 billion and a PE ratio of 22.16.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ ) Earning Somewhat Favorable Media Coverage, Report Finds” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/09/10/johnson-johnson-jnj-earning-somewhat-favorable-media-coverage-report-finds.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.